Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Receivables (2016 - 2025)

Mimedx (MDXG) has disclosed Change in Receivables for 14 consecutive years, with $887000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 60.63% to $887000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.4 million through Dec 2025, up 934.25% year-over-year, with the annual reading at $26.4 million for FY2025, 934.25% up from the prior year.
  • Change in Receivables hit $887000.0 in Q4 2025 for Mimedx, down from $11.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $11.0 million in Q3 2025 to a low of -$4.0 million in Q2 2024.
  • Historically, Change in Receivables has averaged $2.9 million across 5 years, with a median of $2.3 million in 2022.
  • Biggest five-year swings in Change in Receivables: tumbled 89200.0% in 2022 and later soared 1055.72% in 2025.
  • Year by year, Change in Receivables stood at $9.5 million in 2021, then crashed by 72.21% to $2.6 million in 2022, then skyrocketed by 111.13% to $5.6 million in 2023, then tumbled by 59.61% to $2.3 million in 2024, then crashed by 60.63% to $887000.0 in 2025.
  • Business Quant data shows Change in Receivables for MDXG at $887000.0 in Q4 2025, $11.0 million in Q3 2025, and $7.3 million in Q2 2025.